Philip Grant, MD
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Philip Grant, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03549689 · Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)Philip Grant · withdrawn · HIV/AIDS, HIV-1-infection, Osteopenia · principal investigator
- Ph4NCT02964091 · Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing WorldPartners in Health · completed · Chronic Hepatitis C · principal investigator
- Ph2/Ph3NCT02499978 · Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated ToxicityStanford University · withdrawn · HIV/AIDS · study director
- N/ANCT01985399 · Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")Stanford University · completed · HIV, AIDS · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.